Join Professors Rebecca Fitzgerald and Peter Sasieni as they discuss the headline findings of the practice-changing BEST3 trial. BEST3 tested a novel device, the Cytosponge, against usual care for detecting the pre-cancerous condition Barrett's Oesophagus. They are joined by Dr Nick Swart for the health economics analysis.